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Objectives This study sought to examine the left ventricular (LV) and right ventricular (RV) function and signs of focal fibro-
sis among long-term survivors of childhood cancer with the use of cardiac magnetic resonance (CMR) imaging.
Background Increased myocardial fibrosis has been detected in the endomyocardial biopsies of survivors. CMR has estab-
lished its role in the assessment of both cardiac function and structure, and focal fibrosis of the myocardium is
detectable with late gadolinium enhancement (LGE).
Methods Sixty-two anthracycline-exposed long-term survivors of childhood cancer were studied at a mean age of 14.6
years. The LV and RV ejection fractions (EFs) and volumes were measured, and LGE was assessed using CMR.
Results An abnormal LV function (EF 45%) was detected in 18% (11 of 62) of the survivors, and an abnormal RV func-
tion was detected in 27% (17 of 62) of the survivors. Subnormal (45%  EF 55%) LV function were demon-
strated in 61% (38 of 62) and subnormal RV function in 53% (33 of 62) of the survivors, respectively. Both the
LV and RV end-systolic and LV end-diastolic volumes were increased compared with reference values. None of
the study patients showed LGE.
Conclusions A considerable proportion of the long-term survivors of childhood cancer with anthracycline exposure demon-
strate signs of cardiac dysfunction detectable by CMR, with the RV also being involved. Yet, myocardial fibrosis
does not seem to be detectable at a median of 7.8 years after anthracycline therapy. (J Am Coll Cardiol 2013;
61:1539–47) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.01.019d
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(Anthracyclines are widely used in the treatment of many
childhood malignancies, but a dose-dependent cardiotoxic-
ity is limiting their use. Late toxicity is defined as cardiac
abnormalities developing no earlier than 1 year after anthra-
cycline treatment, but in some cases it is not discernible
until years or decades later. Late cardiotoxicity can manifest
as subclinical abnormalities in the cardiac function, dilated
cardiomyopathy, and/or heart failure and is usually irrevers-
ible. The cumulative drug dose, mediastinal irradiation,
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21, 2012, accepted January 8, 2013.young age at exposure, female sex, and time post-exposure
are known risk factors for anthracycline cardiomyopathy
also modified by genetic factors (1–3). The prevalence of
subclinical cardiotoxicity is between 0% and 57% (4), and
the prevalence of anthracycline-induced clinical heart failure
is between 0% and 16% (5). Mulrooney et al. (2) reported a
cumulative incidence of congestive heart failure exceeding
7.5% at 30 years among those with a cumulative anthracy-
cline dose250 mg/m2 and 2.5% among those with a lower
ose. Published data also indicate that a left ventricular
LV) dysfunction, frank heart failure (6), and terminal
ardiomyopathy (7) may occur even at lower doses. Child-
ood cancer survivors thus seem at an increased risk for
nthracycline cardiotoxicity with their young age at expo-
ure and longer life expectancy.
Among the cancer survivors, echocardiography has been
idely used in the follow-up of cardiac function, but it has
imitations in sensitivity and problems caused by a subop-
imal acoustic window (8,9). Cardiac magnetic resonance
CMR) imaging is considered a standard of reference in the
ssessment of cardiac function and structure against which
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(10,11). With anthracycline car-
diomyopathy having been thought
to involve mainly the LV, the
follow-up protocols of cancer
survivors have, until recently,
largely neglected the right ventri-
cle (RV) with its complex anat-
omy and scarcity of optimal im-
aging methods. CMR is considered
the best method for visualizing
the RV (12) and thus used in the
follow-up of heart diseases af-
fecting the RV (13).
Many cardiac diseases lead to
fibrosis of the myocardium clas-
sifiable for clinical purposes as
local or diffuse (14). Late gado-
linium enhancement (LGE) in
CMR after the administration of
a gadolinium-chelated contrast
agent (Gd-CA) is a well-established method for assessing focal
fibrosis (15). LGE for fibrosis or deposition of abnormal
substrates in the myocardium can be used in patients with
myocardial infarction, hypertrophic and dilated cardiomy-
opathies, infiltrative diseases, and myocarditis (16).
The pathogenesis of late-onset cardiac toxicity remains
incompletely understood, but evidence exists on myocyte
apoptosis after anthracycline exposure (17), resulting in
myocardial fibrosis detectable on LGE. Steinherz et al. (18)
have reported on increased fibrosis in the endomyocardial
biopsies taken from the RV and at autopsy among the
long-term cancer survivors with anthracycline cardiomyopathy.
The aim of our study was to evaluate the prevalence of
LV and RV dysfunction and signs of focal fibrosis with
CMR among anthracycline-exposed long-term childhood
cancer survivors in a single-center setting.
Methods
Characteristics of the study population. The study pop-
ulation consisted of 62 long-term survivors of childhood
cancer (34 female and 28 male) attending the population-
based pediatric hematology-oncology service of the Tam-
pere University Hospital (Tampere, Finland) between Feb-
ruary 2010 and June 2011. The survivors enrolled had
received anthracyclines (doxorubicin, daunorubicin, idaru-
bicin, or mitoxantrone) as a part of their therapy, had a
minimum follow-up of 5 years, had no congenital heart
disease, and were in remission. Of the 86 survivors initially
recruited, 62 agreed to participate in the study. The body
surface area (BSA) at diagnosis was used to calculate the
cumulative anthracycline dose. Dose conversion to doxoru-
bicin isotoxic equivalents was performed according to the
Children’s Oncology Group recommendations. CMR was
Abbreviations
and Acronyms
BSA  body surface area
CMR  cardiac magnetic
resonance
EDV  end-diastolic volume
EF  ejection fraction
ESV  end-systolic volume
Gd-CA  gadolinium-
chelated contrast agent
LGE  late gadolinium
enhancement
LV  left
ventricle/ventricular
PSIR  phase-sensitive
inversion recovery
RV  right
ventricle/ventricular
TI  inversion timeperformed only for study purposes with only 1 child requir-ing anesthesia to achieve optimal images. The institutional
review board of the Tampere University Hospital approved
the study protocol. All survivors and their legal guardian(s)
gave their written informed consent.
The key characteristics of the study patients are presented
in Tables 1 and 2. The age of the survivors was 14.6  3.2
ears. The median (range) age at the time of the malignancy
iagnosis was 3.8 years (0.0 to 13.8 years), and the
ollow-up time was 7.8 years (4.9 to 18.0 years). Their
edian cumulative anthracycline dose was 222 mg/m2 (80
o 419 mg/m2). Seven survivors (11%) had received radio-
therapy involving the heart with a median average cumula-
tive cardiac dose of 10.0 Gy (3.6 to 12.0 Gy). The average
cardiac dose of those without total body irradiation was
derived from the radiotherapy planning charts. The dose
among those with total body irradiation was estimated to
equal the total radiation dose.
Three survivors (5%) had experienced a relapse but at the
time of inclusion were in remission. Three survivors were
taking enalaprile for their cardiomyopathy, and 1 survivor
was taking bisoprolol for a long QT-syndrome. One survi-
vor had an asymptomatic patent ductus arteriosus. One
survivor had had a thrombus resected from the right atrium
during primary therapy but remained asymptomatic.
Clinical Characteristics of Study PatientsTable 1 Clinical Characteristics of Study Patients
Sex
Female 34 (55)
Male 28 (45)
Diagnosis
ALL 28 (45)
AML 7 (11)
Hodgkin disease 6 (10)
Non–Hodgkin lymphoma 7 (11)
Neuroblastoma 7 (11)
Wilms’ tumor 1 (2)
Osteosarcoma 1 (2)
Rhabdomyosarcoma 1 (2)
Other 4 (6)
Anthracycline therapy
Doxorubicin 59 (95)
Daunorubicin 17 (27)
Mitoxantrone 7 (11)
Idarubicin 4 (6)
Radiotherapy involving heart
No 55 (89)
Yes 7 (11)
History of relapse
No 59 (95)
Yes 3 (5)
History of stem cell transplantation
No 54 (87)
Autologous 4 (6)
Allogeneic 4 (6)Values are n (%).
ALL  acute lymphoblastic leukemia; AML  acute myelogenous leukemia.
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CMR was performed on a 1.5-T scanner (Siemens Mag-
netom Avanto; Siemens Healthcare, Erlangen, Germany)
using a 6-channel body array coil with a spine coil and
electrocardiogram gating. Cine TrueFISP slices of 8 mm
without any gap from the heart apex to valves were obtained
in the short-axis plane to analyze the LV and in the axial
plane to analyze the RV function. After injection of gadot-
erate meglumine (0.1 mmol/kg, Dotarem [Guerbet, Roissy,
France]), a 5-min delay was used before obtaining a seg-
mented inversion recovery cine TrueFISP pulse sequence at
the midventricular short-axis level for the determination of
the inversion time (TI) value for the nullification of the
impact of the normal myocardium. Within the next 5 min,
the LGE images were obtained using a TrueFISP gradient
echo sequence with a determined TI (range: 280 to 330 ms)
with a slice thickness of 8 mm in the short axis, 2-chamber
view (vertical long axis through the left atrium and ventri-
cle), 4-chamber view (horizontal long axis), and axial stacks
covering the heart from apex to valves. Thereafter, the
corresponding views were recovered using a phase-sensitive
inversion recovery (PSIR) technique with a constant TI
value of 300 ms. The late-enhancement imaging was per-
formed within 15 min from the beginning of the gadoterate
injection.
In the analysis, ARGUS software (Siemens AG, Munich,
Germany) was used. All measurements were done manually.
The end-systolic and diastolic frames were identified by
determining the ventricular blood-pool areas. The LV
volumes were calculated from the short axis, and the RV
volumes were calculated from the axial cine views. The
aortic outflow tract below the valve and the LV portion of
the slice in the basal region near the left atrium were
included in the LV volume measurements. The same
principles were used for the RV. The free papillary muscles
were included for both the ventricular volumes (Fig. 1). The
LGE in the TrueFISP and PSIR sequences was indepen-
dently analyzed by 2 radiologists (P.S.H, I.R.K.), who also
independently analyzed 15 randomly selected data sets to
evaluate the interobserver variability. One investigator
(PSH) measured 15 data sets twice to assess the intraob-
Clinical Characteristics of Study Patients by SexTable 2 Clinical Characteristics of Study Patients by Sex
Characteristic
Female
(n  34)
Male
(n  28) p Value
Age at study time (yrs) 14.4 3.4 14.9 2.9 0.565
Age at diagnosis (yrs) 3.8 (0.5–12.6) 4.7 (0.0–13.8) 0.760
Follow-up (yrs) 7.7 (4.9–13.6) 7.8 (5.0–18.0) 0.809
Cumulative anthracycline (mg/m2) 224 (108–419) 184 (80–416) 0.372
Height (cm) 156.4 14.1 164.2 16.7 0.051
Weight (kg) 51.9 15.2 58.5 18.7 0.133
BSA (m2) 1.49 0.28 1.63 0.34 0.094
Heart rate (beats/min) 81 16 75 13 0.106
Values are mean  SD or median (range).
BSA  body surface area.server variability.Statistical analysis. Descriptive statistics and analyses were
performed using PASW Statistics 18.0 software (SPSS Inc.,
Chicago, Illinois). Descriptive statistics are presented as the
frequencies and percentages for categoric data and the mean 
SD or median and (range) for continuous data. The CMR
parameters were compared with published data (19,20)
using the 1-sample Student t test. The categoric variables
were compared using the chi-square test (the Fisher exact
test when appropriate). For continuous data, the indepen-
dent samples t test and the Mann-Whitney U test were
used. All tests were 2-sided, and p values 0.05 were
considered statistically significant. The intraobserver and
interobserver variations were assessed using the Bland-
Altman analysis (21).
The reference values for the CMR were deduced from
published data. The LV parameters were compared with the
data of Robbers-Visser et al. (19) describing the short-axis
slices from 60 healthy children age 8 to 17 years. For the RV
analysis, the data of Sarikouch et al. (20) on 99 healthy children
age 8 to 20 years obtained by the axial slices were used.
Abnormally large ventricular volumes were defined as those
exceeding the published mean volumes by at least 2 SD.
Results
Left ventricle. We classified the ejection fraction (EF) as
normal (EF 55%), subnormal (EF 45%  EF 55%), or
abnormal (EF 45%). Of the survivors, 21% (13 of 62) had
a normal LV EF, 61% (38 of 62) had a subnormal LVEF,
and 18% (11 of 62) had an abnormal LVEF. There was a
trend toward a male predominance among those with an
abnormal LVEF (n  11); 29% (8 of 28) were male and 9%
3 of 34) were female (p  0.053). Survivors with an LVEF
45% were older than those with an LVEF45% (16.3 vs.
14.2 years, p 0.047). Eight percent of the survivors (5 of 62)
thought their exercise tolerance was compromised when com-
pared with peers and had an LVEF 55% (range: 44.3% to
54.7%). The cumulative anthracycline dose, age at diagnosis,
and follow-up time seemed not to be associated with the LV
EF (data not shown).
The LV parameters were compared in 3 age groups (8 to
11, 12 to 14, and 15 to 17 years) with the data of
Robbers-Visser et al. (19) (Table 3). No reference data are
available for the short-axis LV parameters taking both age
group and sex simultaneously into account. The LV end-
diastolic volume (EDV) and end-systolic volume (ESV)
were significantly larger in the study group. A total of 82%
(28 of 34) of the female subjects and 100% (28 of 28) of the
male subjects had their LV ESV above the 2 SD of the
reference values. The upper normal limits of the LV EDV
were exceeded by 18% (6 of 34) of the female subjects and
43% (12 of 28) of the male subjects. The LVEF was
significantly lower in all age groups compared with the
reference values. The LV mass did not differ significantly
from the normal values.
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Endocardial and epicardial contours for short-axis images of left ventricular (LV) end-diastole volume (EDV) (A) and end-systole volume (ESV) (B).
Axial images of right ventricular (RV) EDV (C) and ESV (D).
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62) of the survivors, a subnormal RVEF was found in 53%
(33 of 62) of the survivors, and an abnormal RVEF was
found in 27% (17 of 62) of the survivors. More male subjects
(39% [11 of 28]) than female subjects (18% [6 of 34]) had
an abnormal RVEF (p  0.057). The RVEF was not
BSA-Indexed LV Parameters per Age Group Compared With ReferenTable 3 BSA-Indexed LV Parameters per Age Group Compared
Age Group
8–11 yrs (n  14),
12–14 yrs (n  15),
15–17 yrs (n  33) Mean  SD Range
LVEF (%) 8–11 yrs 52.1 5.2 44.0–61.8
12–14 yrs 51.1 4.3 43.5–58.6
15–17 yrs 49.0 6.0 33.7–61.7
LV EDV (ml/m2) 8–11 yrs 84.1 13.4 69.4–118.8
12–14 yrs 89.5 11.0 71.4–117.8
15–17 yrs 91.1 15.8 58.7–131.3
LV ESV (ml/m2) 8–11 yrs 40.3 8.0 29.6–60.5
12–14 yrs 43.8 6.2 36.0–52.8
15–17 yrs 46.3 9.5 28.9–71.9
LV SV (ml/m2) 8–11 yrs 43.8 7.9 31.6–58.2
12–14 yrs 45.8 7.2 34.8–65.1
15–17 yrs 44.7 10.2 27.3–71.0
LV mass (g/m2) 8–11 yrs 64.4 13.3 44.0–92.5
12–14 yrs 68.7 10.1 53.6–91.2
15–17 yrs 68.2 12.8 50.4–90.9
*Robbers-Visser D, Boersma E, Helbing WA. Normal biventricular function, volumes, and mass in
BSA body surface area; CI confidence interval; EDV end-diastolic volume; EF ejection fra
olume.
BSA-Indexed RV Parameters per Sex and Age Group Compared WitTable 4 BSA-Indexed RV Parameters per Sex and Age Group C
Age Group Mean  SD R
Female (n  34)
8–15 yrs (n  23),
16–20 yrs (n  11)
RVEF (%) 8–15 yrs 51.2 8.4 26.
16–20 yrs 47.8 8.9 30.
RV EDV (ml/m2) 8–15 yrs 84.6 16.3 56.
16–20 yrs 77.8 12.3 56.
RV ESV (ml/m2) 8–15 yrs 41.5 11.8 26.
16–20 yrs 41.2 11.7 20.
RV SV (ml/m2) 8–15 yrs 43.1 10.2 24.
16–20 yrs 36.6 5.6 23.
Male (n  28)
8–15 yrs (n  17),
16–20 yrs (n  11)
RVEF (%) 8–15 yrs 48.8 6.7 38.
16–20 yrs 40.6 8.3 28.
RV EDV (ml/m2) 8–15 yrs 89.6 23.5 60.
16–20 yrs 102.0 14.2 81.
RV ESV (ml/m2) 8–15 yrs 45.7 12.4 26.
16–20 yrs 60.7 12.8 41.
RV SV (ml/m2) 8–15 yrs 43.9 14.3 28.
16–20 yrs 41.3 9.4 27.
*Sarikouch S, Peters B, Gutberlet M, et al. Sex-specific pediatric percentiles for ventricular size and
MRI flow. Circ Cardiovasc Imaging 2010;3:65–76.
BSA  body surface area; CI  confidence interval; EDV  end-diastolic volume; EF  ejection fractionassociated with the cumulative anthracycline dose, age at
diagnosis, or follow-up time (data not shown).
For the RV parameters, a comparison with the reference
values was done in 2 age groups (8 to 15 years and 16 to 20
years) and separately for female and male subjects (20)
(Table 4). The RV ESV and stroke volume were signifi-
alues by 1-Sample t TestReference Values by 1-Sample t Test
Mean  SD From
Reference
Values*
Range From
Reference
Values* p Value
95% CI of the
Difference
Lower Upper
69 5 NA 0.001 19.9 13.9
69 5 NA 0.001 20.3 15.5
69 5 NA 0.001 22.1 17.8
71 8 58–87 0.003 5.3 20.8
78 9 66–97 0.001 5.4 17.6
77 12 62–102 0.001 8.5 19.7
22 5 15–33 0.001 13.7 22.9
24 5 16–34 0.001 16.3 23.2
25 6 18–39 0.001 18.0 24.7
NA NA ND ND ND
NA NA ND ND ND
NA NA ND ND ND
59 8 44–84 0.153 2.3 13.1
66 11 54–87 0.310 2.8 8.3
70 17 42–98 0.417 6.4 2.7
n aged 8 to 17 years. J Magn Reson Imaging 2009;29:552–9.
SV end-systolic volume; LV ventricular; NA not available; ND not determined; SV stroke
ference Values by 1-Sample t Testred With Reference Values by 1-Sample t Test
Mean  SD From
Reference Values* p Value
95% CI of the
Difference
Lower Upper
62.6 3.6 0.001 15.0 7.8
62.1 6.0 0.001 20.3 8.3
.0 78.3 9.7 0.076 0.7 13.4
.2 79.7 10.3 0.629 10.1 6.4
29.2 4.6 0.001 7.2 17.4
30.4 6.9 0.012 3.0 18.7
49.1 6.8 0.01 10.4 1.6
49.3 6.3 0.001 16.4 8.9
62.3 4.3 0.001 16.9 10.0
60.0 4.4 0.001 24.9 13.8
.3 82.9 12.6 0.256 5.4 18.8
.7 90.2 10.9 0.02 2.3 21.3
31.3 6.1 0.001 8.1 20.8
36.1 6.3 0.001 16.0 33.2
51.6 8.4 0.042 15.1 0.3
54.1 7.3 0.001 19.1 6.5
s reference values for cardiac MRI: assessment by steady-state free-precession and phase-contrastce VWith
childreh Reompa
ange
5–65.4
6–64.5
6–113
3–100
0–67.1
0–64.0
3–55.4
3–43.6
0–61.5
8–54.7
5–142
8–128
9–66.0
8–85.3
0–80.6
0–59.8
mass a; ESV  end-systolic volume; RV  right ventricular; SV  stroke volume.
ventricu
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female and 64% (18 of 28) of the male subjects had their RV
ESV above the 2 SD of the reference values. An abnor-
mally large RV EDV was found in 15% (5 of 34) of the
female subjects and 21% (6 of 28) of the male subjects. Only
the male subjects aged 16 to 20 years had a significantly
larger RV EDV compared with the reference values. The
RVEF was significantly lower in all age groups compared
with reference values. The RV mass was not measured in
our study.
Cardiac irradiation. Those with a history of cardiac irra-
diation did not have larger ventricular volumes or an altered
LV mass compared with the other survivors (Table 5).
Among the irradiation-exposed subjects, 29% (2 of 7) had
their LV EDV, 86% (6 of 7) had their LV ESV, and 14%
(1 of 7) had their RV ESV above the 2 SD of the
reference values.
None of the study patients showed LGE. The intraob-
server and interobserver data are presented in Figure 2 and
Table 6. The limits of agreement were defined as1.96 SD
from the mean between 2 measurements. Intraobserver
variability was lower than interobserver variability. Interob-
server variability was lower for the LV than for the RV.
Discussion
The current study is the first to report on the LGE and LV
and RV function with CMR in a pediatric population after
anthracycline treatment. The data unequivocally document
a marked LV and RV dysfunction without signs of focal
myocardial fibrosis among the anthracycline-exposed long-
term survivors of childhood cancer. However, the myocar-
dial dysfunction remains mostly asymptomatic at approxi-
mately 1 decade post-therapy. Only 6% (4 of 62) were
taking medication, and 92% of the total considered their
exercise tolerance normal. Armstrong et al. (9) found an
abnormal LVEF with CMR in 32% of their adult survivors
of childhood cancer previously undiagnosed with cardiotox-
icity. Yet, although asymptomatic, the survivors may be at
risk of a symptomatic heart failure on exposure to a stress
such as pregnancy (22) or hypertension (23), warranting a
regular cardiologic follow-up and lifestyle counseling.
CMR volumetry and function. CMR imaging is a well-
established, accurate, reproducible, and noninvasive method
Comparison of Ventricular Volumes and Mass BSurvivor Exposed or Unexp sed to Cardiac IrraTable 5 Compariso of Ventricular VolumesSurvivors Exposed or Unexposed to
Survivors With Cardiac
Irradiation (n  7)
LV EDV (ml/m2) 83.6 19.0
LV ESV (ml/m2) 41.1 9.9
RV EDV (ml/m2) 77.6 15.4
RV ESV (ml/m2) 35.2 13.9
LV mass (g/m2) 61.7 14.4
Values are mean  SD.
EDV  end-diastolic volume; ESV  end-systolic volume; LV  leftfor assessing both the LV and RV function (10,24). Ad-vantages over echocardiography include independence of
the acoustic window and geometric assumptions, as well as
freely selectable imaging planes. Among the survivors of
childhood cancer, the impact of factors such as obesity,
postoperative abnormalities of the thorax, or a marked
dilatation of the ventricles emphasizes the benefits of
CMR. Furthermore, CMR remains optimal for the
imaging of cardiomyopathies with an ability to visualize
the myocardium (25).
Until recently, the CMR reference values in children have
been based on the gradient-echo sequences from a limited
number of small studies (26–28). Recent papers (19,20)
report pediatric data using steady-state, free-precession,
gradient-echo sequences, currently the standard method in a
functional and volumetric CMR. The availability of age
group–specific data (19,20) made it possible for us to
compare the ventricular volumes with the pediatric refer-
ence values.
The screening for an anthracycline-induced cardiotoxicity
has previously focused on the LV. The normal values for the
fractional shortening and EF are age-independent, facilitat-
ing their use in a pediatric population. However, the
BSA-indexed ventricular volumes offer a valuable tool for an
earlier detection of overload changes in the heart chambers.
A sizeable proportion of our study patients had abnormally
large LV and RV ESVs, with the EDVs being less affected.
This may represent an early stage in the progression of
dysfunction. The fractional shortening and EF may remain
within the normal limits despite LV dilatation. In many
heart diseases, the BSA-indexed ventricular volumes are
used at the clinic (13). Therefore, abnormally large ventric-
ular volumes with a normal EF emphasize the need for a
regular cardiac follow-up among pediatric cancer survivors.
Our results are in agreement with the data of Oberholzer
et al. (29) on the biventricular cardiac function of
anthracycline-exposed pediatric patients. One-half of their
patients had an LVEF 55% but remained asymptomatic,
and the RVEF after chemotherapy was 48.2  7.1%,
reflecting an additional impairment in the RV function (29).
The cardiotoxic effects of irradiation are more diverse
than those of anthracyclines and are reported to be predom-
inantly restrictive (30). Adams et al. (31) reported reduced
LV dimensions by echocardiography among mediastinal
ennMass Between
iac Irradiation
Survivors Without Cardiac
Irradiation (n  55) p Value
89.8 13.6 0.278
44.8 8.6 0.300
89.2 19.0 0.128
47.4 13.3 0.027
68.2 11.9 0.190
lar; RV  right ventricular.etwediatioand
Cardirradiation–exposed long-term survivors of Hodgkin dis-
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Figure 2 Bland-Altman Plots for CMR Intraobserver and Interobserver Analyses
Intraobserver plots are shown on the left, and interobserver plots are shown on the right. Interobserver analyses were independently reviewed by 2 of the investigators
(IRK and PSH). The bold horizontal line represents the mean difference, and the dashed horizontal lines represent 1.96 SD from the mean between the 2 measure-
ments. CMR  cardiac magnetic resonance; EDV  end-diastolic volume; ESV  end-systolic volume; LV  left ventricular; RV  right ventricular.
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Cardiac Effects of Anthracyclines Evaluated by CMR April 9, 2013:1539–47ease. In our study, there was a trend toward smaller
ventricular volumes among the cardiac irradiation–exposed
survivors. Yet, because of the small sample size and heter-
ogeneity of the cohort, reliable conclusions could not be
drawn.
Late gadolinium enhancement. A delayed enhancement
could not be detected even though 2 different methods were
used: one using the changing TI time and one using a
sensitive PSIR method with a constant TI time. Gd-CA
doses in the LGE imaging of various heart diseases have
varied between 0.1 and 0.2 mmol/kg (32–34). It remains
unsettled whether a larger Gd-CA dose could have pro-
duced more LGE among our study patients, but for safety
reasons the lower recommended dose was used (35).
Data on the myocardial LGE among anthracycline-
exposed long-term survivors of childhood cancer have not
been reported. Wassmuth et al. (36) studied 22 adult
patients and reported on a transient increase in the myo-
cardial enhancement early after the administration of an-
thracycline. Perel et al. (37) described 2 adults with an
anthracycline cardiomyopathy, LV dysfunction, and suben-
docardial LGE years after chemotherapy, with one having
LGE in the RV. Furthermore, LGE also was detected in
29% of 36 adult patients with mediastinal radiotherapy for
Hodgkin disease more than 2 decades earlier (38).
Data on fibrosis in anthracycline-induced cardiomyopa-
thy remain limited but indicate a prolonged process (18,37).
The incidence of frank cardiac pathology increases with
time since exposure. The estimated risk of developing
cardiomyopathy after anthracycline therapy has been re-
ported to be 4.5% at 10 years and increases to 9.8% at 20
years after therapy among patients with cumulative doses of
300 mg/m2 (39). The median follow-up of 7.8 years in
ur study may not have been long enough for myocardial
brosis to develop. This may be partly due to age-related
ardiovascular events promoting cardiac damage and
yocardial fibrosis, emphasizing the importance of life-
tyle counseling among the long-term survivors. Further-
ore, endomyocardial biopsies remain infrequently per-
ormed during pediatric follow-up. This may negatively
ffect the possibility of documenting myocardial fibrosis
mong children.
A diffuse myocardial fibrosis cannot be visualized on
Intraobserver and Interobserver Variability (BlanTable 6 Intraobserver and Interobserver Var
LV EDV
Intraobserver variability
Mean difference 4.9
Limits of agreement 20.0 to 29.8
Interobserver variability
Mean difference 14.7
Limits of agreement 38.0 to 8.6
Values are given in milliliters.
EDV  end-diastolic volume; ESV  end-systolic volume; LV  ventGE with diffuse fibrosis being nulled out to highlight focalbrosis and information on a possible background diffuse
brosis thus being obliterated (14). Flett et al. (40) recently
eported on a novel, noninvasive equilibrium-contrast CMR
pproach to detect the diffuse fibrosis validated using
urgical myocardial biopsies in patients with aortic stenosis
nd hypertrophic cardiomyopathy. Bernaba et al. (41) found
oth interstitial and diffuse fibrosis in the myocardial tissue
f 10 adult patients with an anthracycline-induced cardio-
yopathy. It is conceivable that some of our study patients
ay have diffuse fibrosis not detectable with the technique
sed.
Published data (18,37,41) clearly indicate that some
atients with anthracycline exposure will have focal or
iffuse fibrosis detectable on LGE or through an
quilibrium-contrast CMR. The limited number of reports
n an established myocardial fibrosis with anthracycline
ardiomyopathy invariably document a concomitant symp-
omatic heart failure, and many of these patients have
ndergone heart transplantation (18,37,41).
tudy limitations. Because of ethical reasons and resource
imitations, we had no own healthy controls analyzed with
MR.
onclusions
markedly high proportion of the long-term survivors of
hildhood cancer with anthracycline exposure appear to
ave a cardiac dysfunction detectable by CMR with the
V also being involved, but without focal myocardial
brosis. In the follow-up of these patients, the CMR is
ighly usable, particularly among those with poor acous-
ic windows or the RV function at focus. Whether a
onger follow-up will render putative anthracycline-
nduced myocardial fibrosis detectable (e.g., LGE) among
he long-term survivors of childhood cancer remains to be
stablished.
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